Even though there are no definitive data conferring ovarian chemoprotective effect to GnRH analogues, that drugs present a second beneficial effect on women submitted to chemotherapy, since they may present altered menstrual flows, especially hypermenorrhea and menorrhagia secondary to the common thrombocytopenia induced by chemotherapeutic agents. Here, GNRH1 is linked to Menorrhagia.